Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets
NEW YORK, April 21, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Sanofi S.A. ("Sanofi") for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.
- NEW YORK, April 21, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Sanofi S.A. ("Sanofi") for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.
- These therapeutics generated 4 Investigational New Drug(IND) applicationsand over 104 clinical studies involving more than 15,000 subjects across a number of CNS indications.
- Terran plans to quickly advance the development of these assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need.
- Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.